Skip to content


Exit type:
Placement of blocks of shares on AIM

Genedrive is a molecular diagnostics company developing and commercialising a low cost, rapid, simple to use and robust point of need molecular diagnostics platform. With the global shift of healthcare turning to the testing and treatment of COVID-19, the company refocused part of its resources to the development of two SARS-COV-2 tests. This, combined with a long term supply agreement with the US Dept of Defense for the company’s biohazard test, and progress on its antibiotic induced hearing loss test for neo-natals, resulted in a significant increase in the Genedrive share price.

Calculus have fully exited by selling down shares that were listed on AIM achieving average ROI of 2.1x.